Serum protein and PBMC mRNA expressions of IL-1β, IL-6 and TNF-α in first-episode schizophrenia

Xue-Qin SONG,Jing-Ping ZHAO,Lu-Xian L(U),Wen-Qiang LI

DOI: https://doi.org/10.3321/j.issn:1000-2790.2007.23.026

2007-01-01

Abstract:AIM:To measure in parallel the serum levels and the peripheral blood mononuclear cell (PBMC) mRNA expression of IL-1β, IL-6 and TNF-α both before and after exposure to risperidone during a 4-week treatment protocol for schizophrenia, and to determine whether the levels of these factors were correlated with clinical variables. METHODS: ELISA and reverse transcription-polymerase chain reaction (RT-PCR) techniques were applied to analyze serum levels and PBMC mRNA expression of IL-1β, IL-6 and TNF-α in 83 schizophrenia patients and 65 healthy control subjects. RESULTS: ① Serum IL-1β, IL-6 and TNF-α levels in the schizophrenia group both pre- and post-treatment with risperidone were significantly higher than those in the control subjects (P<0.05). Serum IL-1β levels of the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). ② Serum TNF-α levels of the negative subtype patients were significantly higher than those of the positive subtype patients before treatment (P<0.05). Serum IL-1β of the schizophrenia group and TNF-α levels of the negative subtype patients decreased significantly after 4-week treatment (P<0.05). Serum IL-6 levels of the familial schizophrenia were significantly higher than those of the sporadic schizophrenia before treatment (P<0.05). Serum IL-1β levels of the schizophrenia group and serum TNF-α levels of the familial schizophrenia decreased significantly after 4-week treatment (P<0.05). ③ There was significant correlation between the levels of TNF-α and the severity of negative symptom clusters evaluated by the PANSS (r=0.412, P<0.05). There was significant correlation between the difference of serum IL-1β levels pre- and post- treatment and the rate of the decreased PANSS (r=0.368, P<0.05). ④ IL-1β, IL-6 and TNF-α mRNA expression in the PBMC from the schizophrenia group both pre- and post-treatment were significantly higher than those from the control subjects (P<0.05). IL-1β mRNA expression in the PBMC from the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). CONCLUSION: ① Schizophrenia patients are in a state of immune activation. The difference of serum IL-1β level between pre- and post-treatment with neuroleptic may be a sensitive parameter of illness recovery. ② Changes in the immune system are involved in the pathophy-siology of schizophrenia. ③ PBMC of schizophrenia patient is activated and may be one of major sources of cytokines.